Jazz Pharmaceuticals received conditional marketing authorization in Europe and specific product approvals for Ziihera in Norway, Iceland, and Liechtenstein on July 6, 2025.
3 reports, 0 independent
Updated Jul 6
Gone quiet
- Reports
- 3
- Developments
- 3
- Repetition
- 67%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Jazz Pharmaceuticals received conditional marketing authorization in Europe and specific product approvals for Ziihera in Norway, Iceland, and Liechtenstein on July 6, 2025.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Jazz Pharmaceuticals plans U.S. launch of Ziihera.Sub-event
- Analyst raised price target for Jazz Pharmaceuticals from $281 to $307, driven by product adoption and revenue growth.Sub-event
- Jazz Pharmaceuticals gains conditional marketing authorization in Europe and specific country approvals for Ziihera.
Keep exploring
The entities involved
-
Jazz Pharmaceuticals
Irish tax-registered pharmaceutical corporation
-
Iceland
Nordic island country in the North Atlantic Ocean
-
Norway
country in Northern Europe
-
Liechtenstein
country in Central Europe
Related events
Coverage
Newest first; wire copies grouped- Unknown outlet
- Unknown outlet
- Unknown outlet